Press Releases & Presentations

 
(Swipe to view full table)
  Date Title and Summary View

Jun 7, 2016

Accelerate Diagnostics to Present at the 36th Annual Growth Stock Conference
TUCSON, Ariz., June 07, 2016 (GLOBE NEWSWIRE) -- Accelerate Diagnostics, Inc. announced today that Lawrence Mehren, the company's president and chief executive officer, is scheduled to present to investors at the 36th Annual Growth Stock Conference hosted by William Blair & Company, L.L.C. on June 15, 2016 at 8:00 a.m. Central Time at the Four Se...Read more

Apr 25, 2016

Accelerate Diagnostics Schedules First-Quarter 2016 Results Announcement and Webcast
TUCSON, Ariz., April 25, 2016 (GLOBE NEWSWIRE) -- Accelerate Diagnostics, Inc. announced today it will report first-quarter 2016 financial results after market close on Thursday, May 12, 2016. President and Chief Executive Officer, Lawrence Mehren, joined by Steve Reichling, Chief Financial Officer, will host an audio webcast to review the f...Read more

Apr 10, 2016

Accelerate Diagnostics to Present Data at European Congress
TUCSON, Ariz., April 10, 2016 (GLOBE NEWSWIRE) -- Accelerate Diagnostics, Inc. ("Accelerate") announced today it will present data related to the Accelerate Pheno™ system and Accelerate PhenoTest™ BC kit for positive blood cultures while attending the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Amste...Read more

Apr 10, 2016

Investor Overview

Jan 29, 2016

District Court Dismisses Lawsuit Against Accelerate Diagnostics
TUCSON, Ariz., Jan. 29, 2016 (GLOBE NEWSWIRE) -- Accelerate Diagnostics, Inc. (Nasdaq:AXDX) ("Accelerate Diagnostics") announced today that the United States District Court for the District of Arizona granted Accelerate Diagnostics' Motion to Dismiss the class action lawsuit filed against it in March of 2015. In granting the company's motion, the...Read more

Jan 5, 2016

Accelerate Diagnostics to Present at the J.P. Morgan 34th Annual Healthcare Conference on January 12th
TUCSON, Ariz., Jan. 05, 2016 (GLOBE NEWSWIRE) -- Accelerate Diagnostics, Inc. (Nasdaq:AXDX) announced today that Lawrence Mehren, President and Chief Executive Officer, is scheduled to present at the J.P. Morgan 34th Annual Healthcare Conference in San Francisco, CA on Tuesday, January 12th at 7:30 AM PST / 10:30 AM EST. A live audio webcast...Read more

Dec 15, 2015

Accelerate Diagnostics Completes $109 Million Offering, Underwriters Exercise in Full Their Option to Purchase Additional Shares
TUCSON, Ariz., Dec. 15, 2015 (GLOBE NEWSWIRE) -- Accelerate Diagnostics, Inc. (Nasdaq:AXDX) announced that it completed a public offering of 6,426,471 shares of common stock today at a previously disclosed price per share of $17.00 which includes 838,235 shares issued and sold to the underwriters who exercised in full their option to purchase add...Read more

Dec 9, 2015

Accelerate Diagnostics Announces Pricing of Public Offering of Common Stock
TUCSON, Ariz., Dec. 9, 2015 (GLOBE NEWSWIRE) -- Accelerate Diagnostics, Inc. (Nasdaq:AXDX) today announced the pricing of an underwritten public offering of 5,588,236 shares of its common stock at a price to the public of $17.00 per share. All of the shares are being sold by Accelerate Diagnostics. The gross proceeds to Accelerate Diagnostics from ...Read more

Dec 8, 2015

Accelerate Diagnostics Announces Proposed Public Offering of Common Stock
TUCSON, Ariz., Dec. 8, 2015 (GLOBE NEWSWIRE) -- Accelerate Diagnostics, Inc. (Nasdaq:AXDX) today announced that it has commenced an underwritten public offering of $80 million of shares of its common stock. All of the shares are being offered by Accelerate Diagnostics. In addition, Accelerate Diagnostics expects to grant the underwriters of the off...Read more

Dec 2, 2015

Accelerate Diagnostics Reports Positive Results From Pilot Study of Its Investigational ID/AST System and Blood Culture Assay Kit and Initiation of Trial to Support FDA Clearance
TUCSON, Ariz., Dec. 2, 2015 (GLOBE NEWSWIRE) -- Accelerate Diagnostics, Inc. announced positive findings from a multicenter pilot study to evaluate external performance of its ID/AST System and Blood Culture Assay Kit. Based on the results of the study, the company also announced the initiation of its clinical trial for submission to the U.S. Food ...Read more
FirstPrevious
1
2
3
4
...
6
Next Last

= add release to Briefcase
NASDAQ: AXDX
$ 22.88
+0.13
(0.59%)
9:38 AM ET on Mar 24, 2017
Day High: 22.91
Day Low:  22.75
Volume:    3,819
Delayed ~20 min., by eSignal.

Want to receive investor-related news and updates?

Join our mailing list

Other updates